<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12122">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02949128</url>
  </required_header>
  <id_info>
    <org_study_id>ALXN1210-aHUS-311</org_study_id>
    <secondary_id>2016‐002027‐29</secondary_id>
    <nct_id>NCT02949128</nct_id>
  </id_info>
  <brief_title>Single Arm Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Patients With Atypical Hemolytic Uremic Syndrome (aHUS)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the efficacy of ALXN1210 to control disease activity
      in adolescent and adult patients with aHUS who have not previously used a complement
      inhibitor.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete TMA response</measure>
    <time_frame>26 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dialysis requirement status</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Complete TMA Response</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete TMA Response status over time</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed value and change from baseline in estimated glomerular filtration rate (eGFR)</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in chronic kidney disease (CKD) stage</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in hematologic parameters (platelets, LDH, hemoglobin)</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Increase in hemoglobin ≥ 20g/L from baseline</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in quality of life, as measured by the EQ-5D-3L (all patients)</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in quality of life, as measured by the FACIT Fatigue Version 4 questionnaire (patients ≥ 18 years of age)</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in quality of life, as measured by the Pediatric FACIT Fatigue questionnaire (patients 12 to &lt; 18 years of age)</measure>
    <time_frame>26 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Atypical Hemolytic Uremic Syndrome (aHUS)</condition>
  <arm_group>
    <arm_group_label>ALXN1210</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ALXN1210</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALXN1210</intervention_name>
    <description>Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight.
≥ 40 to &lt;60 kg: 2400 mg loading, then 3000 mg every 8 weeks
≥ 60 to &lt;100 kg: 2700 mg loading, then 3300 mg every 8 weeks
≥100 kg: 3000 mg loading, then 3600 mg every 8 weeks</description>
    <arm_group_label>ALXN1210</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female ≥ 12 years of age and weighing ≥ 40 kg at the time of consent.

          2. Evidence of thrombotic microangiopathy (TMA), including low platelet count, hemolysis
             (breaking of red blood cells inside of blood vessels), and decreased kidney function

          3. Documented meningococcal vaccination not more than 3 years prior to dosing, under 18
             also requiring vaccination against Streptococcus pneumoniae and Haemophilus
             influenzae

          4. Female patients of childbearing potential must use highly effective contraception
             starting at screening and continuing until at least 8 months after the last dose of
             ALXN1210

        Exclusion Criteria:

          1. ADAMTS13 deficiency (Activity &lt; 5%)

          2. Shiga toxin-related hemolytic uremic syndrome (STEC-HUS)

          3. Positive direct Coombs test

          4. Pregnancy or breastfeeding

          5. Identified drug exposure- related hemolytic uremic syndrome (HUS)

          6. Bone marrow transplant (BMT)/hematopoietic stem cell transplant (HSCT) within last 6
             months prior to start of Screening

          7. HUS related to vitamin B12 deficiency

          8. Systemic sclerosis (scleroderma), systemic lupus erythematosus (SLE), or
             antiphospholipid antibody positivity or syndrome

          9. Chronic dialysis (defined as dialysis on a regular basis as renal replacement therapy
             for ESKD)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexion Pharmaceuticals, Email for a Complete Site List</last_name>
    <email>clinicaltrials@alexion.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Whittier</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Adelaide</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ClinicalTrial Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Korea, Republic of</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 14, 2017</lastchanged_date>
  <firstreceived_date>October 25, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Hemolysis</mesh_term>
    <mesh_term>Azotemia</mesh_term>
    <mesh_term>Hemolytic-Uremic Syndrome</mesh_term>
    <mesh_term>Atypical Hemolytic Uremic Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
